市場調査レポート
商品コード
1450999
止血剤(止血材)の市場レポート:製品、用途、製剤形態、地域別、2024-2032Hemostats Market Report by Product, Application, Formulation, and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
止血剤(止血材)の市場レポート:製品、用途、製剤形態、地域別、2024-2032 |
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2~3営業日
|
世界の止血剤(止血材)市場規模は2023年に35億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに58億米ドルに達し、2024-2032年の成長率(CAGR)は5.73%になると予測しています。外科手術の増加、技術の進歩、ヘルスケアインフラの拡大、医療従事者の意識の高まり、高齢化人口の増加などが市場を後押しする主な要因です。
複雑な手術、低侵襲手術、外傷症例などの外科手術の発生率が上昇していることが、止血剤(止血材)および器具の需要を煽る主な要因となっています。さらに、世界人口の高齢化が進むにつれて、心血管疾患やがんなど、外科的介入を必要とする慢性疾患の有病率が増加しており、市場の拡大を後押ししています。また、医療技術の進歩により、有効性と安全性が向上した革新的な止血剤(止血材)が市場開拓され、市場の成長を後押ししています。さらに、合併症を減らし、患者の予後を改善するための効果的な止血の重要性に対するヘルスケア専門家の意識の高まりが、止血剤(止血材)の採用を後押ししています。さらに、新興市場におけるヘルスケアインフラの拡大と医療費の増加は、外科治療へのアクセスの普及に伴い、止血剤(止血材)市場の成長に寄与しています。
外科手術の増加
世界の外科手術の増加は、止血剤(止血材)市場の重要な促進要因です。外科的介入は、盲腸のような日常的な処置から臓器移植のような複雑な手術まで、様々な病状の治療に不可欠です。世界人口の増加と高齢化が進むにつれ、心血管疾患、がん、整形外科疾患などの慢性疾患の有病率も上昇傾向にあります。このため、外科的介入、ひいては止血剤(止血材)と器具の需要が増加しています。止血剤(止血材)は、出血を制御し、合併症のリスクを低減し、患者の転帰を改善するために、これらの処置において極めて重要です。
技術の進歩
医療技術の進歩は止血剤(止血材)市場の成長において極めて重要な役割を果たしています。こうした技術革新により、より効果的で安全性の高い止血剤(止血材)が開発されています。例えば、新しい止血剤(止血材)は生体適合性や生体吸収性のある材料を組み込んでいることが多く、副作用のリスクを低減しています。さらに、止血剤(止血材)の中には、より迅速に作用するように設計されているものもあり、貴重な手術時間を節約することができます。さらに、低侵襲手術などの手術手技の進歩により、これらの手技に合わせた特殊な止血器具の需要が高まっています。技術革新は引き続き製品開拓の原動力となり、市場全体を強化しています。
新興市場におけるヘルスケア・インフラの拡大
新興市場、特にアジア、ラテンアメリカ、アフリカでは、ヘルスケア・インフラストラクチャーと医療費の伸びが著しいです。このような拡大は、都市化、可処分所得の増加、医療アクセス改善のための政府イニシアチブの増加によってもたらされています。ヘルスケア施設がより利用しやすくなるにつれ、これらの地域で行われる外科手術の件数は増加傾向にあります。その結果、これらの手術をサポートする止血剤(止血材)と器具の需要が高まっています。ヘルスケア・インフラの拡大は、市場の地理的範囲を拡大するだけでなく、国内外の止血剤(止血材)メーカー間の提携や協力の機会を促進します。
The global hemostats market size reached US$ 3.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.8 Billion by 2032, exhibiting a growth rate (CAGR) of 5.73% during 2024-2032. The rising surgical procedures, technological advancements, expansion of healthcare infrastructure, increasing awareness among healthcare professionals, and a growing aging population are some of the major factors propelling the market.
The rising incidence of surgical procedures, including complex surgeries, minimally invasive procedures, and trauma cases, represents the prime factor fueling the demand for hemostatic agents and instruments. Moreover, as the global population continues to age, the prevalence of chronic diseases necessitating surgical interventions, such as cardiovascular diseases and cancer, is increasing, aiding in market expansion. Concurrent with this, ongoing advancements in medical technology have led to the development of innovative hemostatic products with improved efficacy and safety profiles, further propelling market growth. Additionally, the growing awareness among healthcare professionals about the importance of effective hemostasis to reduce complications and enhance patient outcomes has driven the adoption of hemostats. Furthermore, the expansion of healthcare infrastructure in emerging markets, coupled with increasing healthcare expenditure, is contributing to the growth of the hemostats market as access to surgical care becomes more widespread.
Increasing surgical procedures
The growing number of surgical procedures worldwide is a significant driver for the hemostats market. Surgical interventions are essential for treating various medical conditions, from routine procedures like appendectomies to complex surgeries like organ transplants. As the global population continues to grow and age, the prevalence of chronic diseases such as cardiovascular diseases, cancer, and orthopedic issues is also on the rise. This has led to an increasing demand for surgical interventions, and consequently, hemostatic agents and instruments. Hemostats are crucial in these procedures to control bleeding, reduce the risk of complications, and improve patient outcomes.
Ongoing technological advancements
Advances in medical technology have played a pivotal role in the growth of the hemostats market. These innovations have led to the development of more effective and safer hemostatic products. For example, newer hemostats often incorporate biocompatible and bioabsorbable materials, reducing the risk of adverse reactions. Additionally, some hemostatic agents are engineered to work more rapidly, thus saving valuable surgical time. Moreover, advancements in surgical techniques, such as minimally invasive surgery, have increased the demand for specialized hemostatic tools tailored to these procedures. Technological innovations continue to drive product development, enhancing the overall market.
Healthcare infrastructure expansion in emerging markets
Emerging markets, particularly in Asia, Latin America, and Africa, are experiencing significant growth in healthcare infrastructure and expenditure. This expansion is driven by urbanization, rising disposable incomes, and increased government initiatives to improve healthcare access. As healthcare facilities become more accessible, the number of surgical procedures performed in these regions is on the rise. Consequently, there is a growing demand for hemostatic agents and instruments to support these surgeries. The expansion of healthcare infrastructure not only increases the market's geographical reach but also fosters opportunities for partnerships and collaborations between local and international hemostat manufacturers.
IMARC Group provides an analysis of the key trends in each segment of the global hemostats market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, application, and formulation.
Thrombin Based
Combination Based
Oxidized Regenerated Cellulose Based
Gelatin Based
Collagen Based
Thrombin based dominates the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes thrombin based, combination based, oxidized regenerated cellulose based, gelatin based, and collagen based. According to the report, thrombin based represented the largest segment.
The demand for thrombin based hemostats is being propelled by their rapid action and versatility in managing bleeding in various medical scenarios. Thrombin is a naturally occurring enzyme that plays a crucial role in the blood clotting process. Thrombin-based hemostats offer a targeted and rapid solution for achieving hemostasis, making them particularly valuable in situations where time is critical, such as emergency surgeries and trauma cases. Furthermore, their ability to work independently of the body's clotting mechanisms makes them an attractive option, and their compatibility with other hemostatic agents enhances their versatility in surgical applications, further driving their demand in the healthcare industry.
Orthopedic Surgery
General Surgery
Neurological Surgery
Cardiovascular Surgery
Reconstructive Surgery
Gynecological Surgery
Others
General surgery holds the largest share in the market
A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes orthopedic, general, neurological, cardiovascular, reconstructive, gynecological, and other surgeries. According to the report, general surgery accounted for the largest market share.
The increasing complexity and diversity of surgical procedures represent one of the main factors impelling the need for hemostats in general surgery applications. General surgery encompasses a wide range of operations, from abdominal surgeries to vascular procedures, each posing unique challenges in achieving effective hemostasis. Surgeons are increasingly relying on hemostatic agents and instruments to minimize bleeding, reduce operating time, and enhance patient outcomes. As surgical techniques advance, minimally invasive procedures become more common, necessitating specialized hemostatic tools. Moreover, the expanding aging population with comorbidities requires more surgical interventions, further fueling the demand for reliable and versatile hemostats in general surgery applications.
Matrix and Gel Hemostats
Sheet and Pad Hemostats
Sponge Hemostats
Powder Hemostats
Matrix and gel hemostats dominate the market
The report has provided a detailed breakup and analysis of the market based on the formulation. This includes matrix and gel, sheet and pad, sponge, and powder hemostats. According to the report, matrix and gel hemostats represented the largest segment.
The demand for matrix and gel hemostats is driven by their unique characteristics, such as ease of application and versatility in various medical settings. These hemostatic products offer a user-friendly approach to achieving hemostasis, especially in situations where precise control is essential, such as neurosurgery and ophthalmic procedures. Matrix and gel hemostats conform to irregular wound shapes and adhere well to tissues, ensuring effective sealing of bleeding sites. Apart from this, they often have a resorbable nature, reducing the risk of adverse reactions and minimizing the need for postoperative removal, making them increasingly favored by surgeons and healthcare professionals in diverse clinical applications.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest hemostats market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The North American hemostats market is experiencing significant growth due to the region's aging population driving a higher prevalence of chronic diseases, resulting in an increased demand for surgical interventions, which in turn necessitates the use of hemostatic agents and instruments. Concurrent with this, the well-established healthcare infrastructure in North America, coupled with high healthcare expenditure, allows for extensive adoption of advanced hemostatic technologies and products. Additionally, ongoing technological advancements in the healthcare sector, particularly in the United States, are contributing to the development of innovative hemostatic solutions that are highly sought after by healthcare providers. Furthermore, the region's regulatory environment and stringent quality standards ensure the availability of safe and effective hemostats, further boosting market growth. Apart from this, the rising awareness among healthcare professionals regarding the importance of efficient hemostasis to minimize complications is propelling the North America hemostats market forward.
The global hemostats market is characterized by intense competition, driven by a multitude of established and emerging players striving to gain a competitive edge. Key market participants include leading healthcare companies that have a strong global presence and offer a wide range of hemostatic products. These industry giants engage in extensive research and development efforts to introduce innovative hemostats and expand their product portfolios. Additionally, smaller, niche-focused companies are gaining prominence by offering specialized hemostatic solutions. Collaborations, partnerships, and mergers and acquisitions are common strategies in this dynamic landscape, aimed at strengthening market positions and enhancing product offerings. The competitive rivalry is further fueled by the increasing demand for minimally invasive surgery and the ongoing quest to develop hemostatic agents with enhanced safety profiles, driving continuous innovation and competitiveness in the global hemostats market.
Arch Therapeutics Inc.
Baxter International Inc.
B. Braun Melsungen Aktiengesell
C. R. Bard Inc.
GELITA MEDICAL GmbH
Integra LifeSciences Corporation
Johnson & Johnson
Pfizer Inc.
Stryker Corporation
Teleflex Incorporated
Z-Medica LLC
In July 2023, Baxter International Inc. announced the launch of PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding.
In April 2023, Arch Therapeutics, Inc. a marketer and developer of novel self-assembling wound care and biosurgical products, unveiled its AC5(R) Advanced Wound System ("AC5") at the Symposium on Advanced Wound Care. .